Category Archives: Featured

1933 Industries Partners with Orchid Ventures to Launch the Orchid Essentials Brand in Nevada

1933 Industries Partners with Orchid Ventures to Launch the Orchid Essentials Brand in Nevada

1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE: TGIF) (OTCQX: TGIFF), together with Orchid Ventures Inc. (CSE: ORCD) (OTC: ORVRF) (“Orchid”), are pleased to announce that they have entered into a Supply and Licensing Agreement (“Agreement”) for the manufacturing and distribution of Orchid products into the regulated Nevada cannabis market.

Orchid Ventures, Inc. Logo (CNW Group/1933 Industries Inc.)

Washington -based Orchid Ventures, Inc., through its wholly owned subsidiary, Orchid Brands, LLC, has entered into an exclusive agreement with 1933 Industries’ subsidiary, Alternative Medicine Association LLC (“AMA”), for the purposes of manufacturing, selling and marketing Orchid Essentials Brand products in Nevada , leveraging AMA’s extraction expertise and well-established sales and distribution channels in the state.

Pursuant to the terms of the three-year Agreement, 1933 Industries will purchase Orchid’s PurTec hardware and packaging component products and proprietary terpene blends required for the production of Orchid Essentials products.  AMA will act as the exclusive supplier of the Orchid Essentials Brand Products and future lines, and will also purchase the same hardware components, packaging and terpenes for its own branded products under the same pricing terms. PurTec’s Orchid cartridges are one of the only cartridges for cannabis oil that are emissions tested at AFNOR standards, the strictest guidelines set by the European Union. Orchid’s unique cannabis products and proven intellectual property will complement the Company’s portfolio of trusted brands.

“Bringing the Orchid Essentials brand and PurTec hardware to Nevada as its exclusive carrier is a significant strategic alliance for the Company”, stated Mr. Eugene Ruiz , President of 1933 Industries. “This is a unique opportunity to partner with a company that enables us to expand our offerings with complimentary products, enhance our own delivery systems, improve our terpene profiles and support our sustainability mandate. PurTec’s eco-friendly, plastic free, wind energy manufactured, child resistant retail packaging cartons and high emissions standards provide sustainable product innovation that will differentiate our products with increased consumer appeal. We are excited to launch new, advanced and safe products in the vape segment, within our portfolio of premium products and we look forward to representing the Orchid brand in Nevada .”

“We are pleased to announce another licensing partner for our Orchid brand as we expand the franchise into the state of Nevada . Given our strong brand presence in Southern California , we’ve sold products to many consumers traveling from Nevada , and have previously met with buyers from marquee dispensaries in Vegas, with great reception”, said Mr. Rick Brown , President of Orchid Ventures. “We feel that Orchid is highly differentiated from the existing vape products available in Nevada and that the traveling consumer in this market will help further spread brand awareness of Orchid Essentials. 1933 Industries has been a market leader in Nevada for many years and they have built an extensive retail distribution network through their strong marketing and sales capability. Their focus on quality and innovation coupled with their proven track record as a licensee of other brands, makes 1933 Industries the perfect partner for Orchid inNevada , as we continue to expand the brand nation-wide”.

The launch program will focus on the Orchid Classic 0.5 gram high quality vape product line, with associated packaging consistent with all Nevada Cannabis Compliance Board (CCB) rules and regulations, an optimal selection of terpene profiles and the Orchid 650 mAh batteries, also with associated CCB compliant packaging. Orchid’s extensive all-natural terpene line meets a minimum of 97% purity, are third-party tested and are ISO certified. The products will be available in select dispensaries by December 2020 .

About Orchid Essentials
Orchid Essentials is an Irvine, CA -based cannabis innovation company, that launched in Oregon and California in August 2017 and has since developed a mass-market brand and loyal consumer following with its premium cannabis products and unique vape hardware delivery system. Since July 2019 , Orchid has diversified its efforts and has brought to market innovative services and product offerings to support brands throughout the global cannabis industry. Orchid has diversified its portfolio to include PurTec Delivery Systems, a company that produces, markets and sells clean vaporizer hardware that has been emissions tested against the most stringent standards in the world set forth by the EU and has unrivaled product quality and value pricing. Orchid, through its wholly owned subsidiary, has launched a patented and clinically proven bioavailability solution to increase the absorption of THC and other cannabinoids making products much more effective and an activation time of less than ten minutes. With a continued focus on brand and intellectual property development, Orchid will continue to create new and innovative products and technologies, then bring them to the global cannabis marketplace and set the gold standard for delivery systems whether it’s vape or formulation sciences. Orchid’s management brings significant branding, product development and distribution experience with a proven track record of scaling businesses and building sustainable revenue growth through value-generating partnerships and innovation that creates enterprise value. Learn more athttps://orchidessentials.com/

About 1933 Industries Inc.
1933 Industries is a vertically-integrated, growth-orientated company, focusing on the cultivation and manufacturing of cannabis consumer branded goods in a wide range of product formats. Operating through two subsidiaries, the Company controls all aspects of the value chain with cultivation, extraction, processing, and manufacturing assets supporting its diversified portfolio of cannabis brands and licensing partners. The Company owns 91% of Alternative Medicine Association, LC (AMA), and 100% of Infused MFG LLC.

About Alternative Medicine Association
AMA is a licensed medical and adult-use cannabis cultivation and extraction subsidiary that produces its own branded line of unique cannabis-based products and manufactures third-party brands. With state-of-the-art cultivation and extraction facilities based in Las Vegas, Nevada , AMA seeks to offer medical patients and recreational users alike a cannabis experience that’s exceptional, potent, and consistent in quality.

About Canna Hemp™
With an extensive product line that includes topicals, creams, vapes, elixirs, capsules, dabs, lip balms and pre and post workout recovery sports products, 1933 Industries’ proprietary Canna Hemp™ brand utilizes the power of hemp and CBD to bring natural wellness. The Company’s flagship products, the Canna Hemp™ Relief Cream and Canna Hemp X™ Recovery Cream are recognized as best topicals in the market.  Canna Hemp X™ is a CBD sports recovery cream for athletes, bridging the gap between recovery and top performance. All products are triple and third-party tested for safety with test results embedded via QR codes for traceability.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com .   1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/1933-industries-partners-with-orchid-ventures-to-launch-the-orchid-essentials-brand-in-nevada-301155808.html

SOURCE 1933 Industries Inc.

Published at Tue, 20 Oct 2020 12:59:45 +0000

6 More Lessons We Learned From Our Cannabis Business

6 More Lessons We Learned From Our Cannabis Business

Thomas Hobbes famously stated that life can be “solitary, poor, nasty, brutish and short.” Hobbes could have well been predicting the state of the 21st century cannabis industry, with all its brutishness and nastiness. But we hope this article puts us in solidarity with you and other cannabis business owners, mitigating the solitude, and we hope our advice results in your experience in cannabis being neither poor nor short.

RELATED: 6 Cannabis Business Lessons We Learned Too Late

1. BUDGET FOR THE UNKNOWN

Do not forget to budget for the “Oops, we forgot about…” In our prior article we emphasized understanding the revenue and expense cycles of the particular verticals you operate within (grow, processing, retail, etc.) and to pull them together into a pro forma. Almost every significant expense line will have unanticipated situations come up.

Let’s say you are designing an indoor grow and you are ready to install all your lighting and air management equipment. Your electrician says you need to upgrade the electrical capacity to handle all the equipment you identified. This could easily be a $50,000 additional expense.

Or, as another common example, labor expenses are often underestimated and can drain your cashflow before you start monetizing your crop. If, for example, you are delayed in planting your crop or processing by only a few months, your payroll budget still needs to cover the people you already hired. When doing your pro forma, and before you give any rosy scenarios to investors, it is best to add an additional six months of payroll expense as a “contingent payroll cost” (aka cover your assets (CYA)).

Another consideration for extraction operations: You will be working with highly tuned pieces of equipment that do wear out. A failed compressor, pump or chiller can easily take your machine down for a day or two—which is precious processing time. Budget cash to purchase extra key components to keep on hand—items that may otherwise have to be ordered or reconditioned before you can again get up and running.

2. VERIFY ALL INPUTS INTO YOUR DECISION MAKING

In our prior article we warned against trusting experts; you can apply that idea to your actual decision making.

Everybody is eventually wrong at some point in their cannabis journey. We’d even go so far as to say everybody will be wrong in a very big way at least once. “Everybody” not only includes you, but less intuitively, this lesson includes everybody else internal and external to your core management team. Be very careful of internal and external sources of expertise that advise by assertions. Assertions are dangerous, because if they are delivered with a sense of certainty you may just believe them if you trust the person providing the assertion. People who operate by assertion usually know less than they assert (a term for this, coined by authors Peter Boghossian and James Lindsay in their book “How to Have Impossible conversations,” is the “Unread Library Effect).

All information going into your management team’s decision making needs to be verified and re-verified. One of your best management skills is that of a highly skilled journalist. Such journalists try to have more than one source for their information—they corroborate the information they receive.

3. DON’T AVOID BORING ADMINISTRIVE TASKS

engineered extracts

Engineered Extracts

 

Paperwork and administrative activities can become boring. It takes a special individual to be wired for the constant battle of fighting back against burial by paperwork. It is all boring until the moment there is a problem—then suddenly an existential crisis makes paperwork the opposite of boring. Crisis can include compliance issues around licensing, track-and-trace systems, accounting, payroll, insurance of all kinds, property taxes, payroll taxes, income taxes, warranties, standard operating procedures (SOPs), contracts of all kinds, on and on and on. 

When companies start out, they necessarily put paperwork related to some of those areas on the back burner. They say: “Why do we need SOPs? It is just me and my buddies. We’ll get to that later.” Or, “Insurance in cannabis is so expensive, we’ll probably never need it.” Well the fallacy of that position has again been cast in the spotlight given all the recent fires in the Western states. How many times have you heard someone say they are operating on a handshake deal? How many times do you think these deals work out? Answer: practically never.

One of the most valuable individual(s) you will add to your team is someone with administrative skills. These will be dedicated individuals or key management members who take on the admin duties. Consider them the frontline workers of your company. The company will not exist in the future if all the administrative stuff is not complete. Don’t let the avalanche of paperwork bury your business.

4. STOP ADVOCATING FOR FEDERAL LEGALIZATION RIGHT NOW

There is incessant talk about federal legalization needing to happen immediately.  But we believe that when federal legalization does come, the floodgates of competition will open. Especially if you are a small or mid-size cannabis company, you need as long a runway as possible to get on solid footing and to make yourself a survivor, either as a contender to buy other firms or as a target of a purchase. Each state has struggled with getting legalization correct. While you are dealing with these challenges, you don’t need an overlay of federal challenges to your survival. 

So, what do you advocate for? Advocate for decriminalization, not federal legalization. Advocate for the repeal of IRS Tax Code Section 280E.

Finally, we should all be advocating for the expungement of past criminal records related to cannabis on principle alone.  

5. WHAT KIND OF BUSINESS STRUCTURE SHOULD YOU BUILD?

This is the kind of question that can be hard to ask yourself, especially if you have your heart set on only being in retail or being “the best grower” ever or geeking out permanently with your buddies extracting oil and distillate and hoping to scale to stay in business.  Our admittedly biased opinion is that you have to build some kind of vertically integrated intrastate business.

We don’t have the perfect template, but we define a vertically integrated cannabis business as one in which you are in at least three verticals. For example, you have a grow, a processing division and a retail outlet. Or maybe you have a grow, a distribution business and an intellectual property licensing business. The idea is that each business has its own revenue cycle (see our previous article) and the whole is greater than the sum of its parts. With multiple opportunities to capture margin, why risk everything on one market segment?

Say you own a grow operation and you can wholesale your flower at $1,500 per pound. Let’s assume you don’t have any commission charges for distribution. Now, if you owned a retail shop, you can sell that same pound of flower, broken down into 1/8ths for double or triple the $1,500. You also could create and sell your own oil and distillate without the tolls charged by contracting such services.

We can go on and on with examples, but the important idea is to think through what the long term game plan is. As we noted above, we believe federal legalization will be an extinction event for most cannabis companies. By being vertically integrated and managed well you will become a target for purchase by a much larger firm; or you become a target for investment allowing you to scale your dream. Long-term, there will be standalone firms in each vertical, we grant that outcome. But the standalones will be so large they will basically be part of oligopolies in each vertical. They will serve their purpose, but they won’t create much diversified value. We believe more value will be created per dollar invested in a vertically integrated company than a vertical one only and vertical integration will increase your survival odds.

6. BE AWARE OF WHIZ BANG TECHNOLOGY

Automation, smart devices, artificial intelligence, sensors, remote controls, etc., are all great ideas, and in a perfect world you would have an unlimited budget to try out all these productivity- touting applications.  However, balancing the appeal and benefits of technology with your financial bandwidth is essential. As is exploring any technology’s long-term viability. Choose your initial equipment wisely.  Do your due diligence and talk to actual people who are running the equipment you are looking at to learn about benefits and any specific issues with the equipment.  

IN CONCLUSION

We offer these lessons as the result of our own learning curve. Cannabis is susceptible to the “shiny object syndrome” in that it is easy to get distracted by activities and business deals that are not core to your long-term success. This industry is a slog. The more the slog you endure, the stronger and deeper you build the foundation of your business and elevate your chances for success. As we noted in our prior article, we touched upon the concept that a chain of objective successes is the result of a multiplication of probabilities. And learning from others is the cheapest way to increase any and all of your objectives’ probability weightings.

Loren Picard is CEO at High Desert Flower Inc. in Oregon.

Andrew Olsson is vice president at High Desert Flower Inc. and is the co-founder of Engineered Extracts LLC, also in Oregon.

Published at Tue, 20 Oct 2020 19:44:00 +0000

USDA Approves Hemp Plans For Six Additional States And Three Indian Tribes

USDA Approves Hemp Plans For Six Additional States And Three Indian Tribes

The U.S. Department of Agriculture (USDA) has signed off on hemp plans for six additional states and three Indian tribes this month, with a new batch of approvals coming on Friday.

Illinois, Indiana, Michigan, New Mexico, Oklahoma and South Dakota each had their regulatory proposals accepted within the past two weeks, as did the Comanche Nation, the San Carlos Apache Tribe of Arizona and the Seminole Nation of Oklahoma.

That raises the total number of approved plans to 69.

USDA has been signing off on hemp proposals on a rolling basis over the past year. Last month, it accepted plans from Utah and the Torres Martinez Desert Cahuilla Indians.

Read More

Published at Mon, 19 Oct 2020 16:44:33 +0000

VIVO Cannabis™ Withdraws $5 Million Offering and Provides Business Update

VIVO Cannabis™ Withdraws $5 Million Offering and Provides Business Update

VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (” VIVO ” or the ” Company “) announced today that it is terminating a planned offering of $5.1 million , which it had previously announced on October 6, 2020 .

Vivo Cannabis Logo (CNW Group/VIVO Cannabis Inc.)

The decision to terminate the offering was taken amidst what the Company views as highly unusual trading activity in VIVO’s shares. During the two days following the announcement of the offering, trading volume increased by approximately 8,000% to a cumulative total of 18,980,048 shares, compared with 236,517 shares traded in the two days prior to the announcement.

“While VIVO is unaware of the reasons for the increased trading activity and downward pressure on our stock price, we have reported last week’s highly unusual trading activity to securities regulators,” said Barry Fishman , CEO of VIVO. “We are hoping that in the short-term, trading activity will stabilize at a level that reflects VIVO’s current business fundamentals, recent achievements and future potential.”

The Ontario Securities Commission (OSC) and the Investment Industry Regulatory Organization of Canada (IIROC) jointly announced on October 1, 2020 that they are encouraging the submission of tips related to potential abusive trading in securities of Ontario reporting issuers, including illegal insider trading, market manipulation or abusive short selling. In particular, they are seeking specific and credible evidence about short selling into or ahead of public offerings or private placements of Ontario securities.

https://www.osc.gov.on.ca/en/NewsEvents_nr_20201001_osc-and-iiroc-appeal-for-tips-on-abusive-trading.htm

All VIVO insiders have been and remain subject to a regularly scheduled trading blackout until at least after the Company announces its Q3 2020 results, which is anticipated to be in mid-November.

Business Update

During the past few months, VIVO’s business fundamentals continue to strengthen with several notable successes:

  • Achieved a leading position in the cannabis concentrates category
  • Initiated the largest harvest in the company’s history in Napanee, Ontario
  • Canna Farms was named the fourth most recognized cannabis brand among Canadian consumers
  • Expanded market access, including product listings in Quebec and with Medical Cannabis by Shoppers™
  • Restructured $27 million in current liabilities, leaving the Company with $6.6 million in 6% convertible debt due September 15 , 2022.

About VIVO Cannabis™

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities with proprietary plant-growing technology in Hope, British Columbia and Napanee, Ontario . VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian Bud Collection™ . The Company is expanding its production capabilities and distribution network. Harvest Medicine, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 100,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia . For more information visit: www.vivocannabis.com

Disclaimer for Forward-Looking Information:

All dollar amounts in this news release are in Canadian dollars. Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements regarding potential future offerings by the Company, the potential terms of same, the filing of any prospectus supplement with respect thereto, proposed use of proceeds, assuming completion, the anticipated closing date and the satisfaction of all necessary closing conditions, including the approval of the TSX. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the COVID-19 pandemic may last longer and have a more significant impact on the Company’s operations, financing abilities, the Canadian cannabis industry, or the global economy generally, than currently expected; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the three months ended June 30, 2020, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE VIVO Cannabis Inc.

Published at Fri, 16 Oct 2020 11:20:47 +0000

Michigan Governor Signs Expungement Bill Into Law, Illinois Collects More than $100 Million in Cannabis Tax Revenue: Week in Review

Michigan Governor Signs Expungement Bill Into Law, Illinois Collects More than $100 Million in Cannabis Tax Revenue: Week in Review

Multistate cannabis operator Cresco Labs is committed to being a responsible player in the rapidly growing industry, and has now set out to help other companies build brands the right way through the release of its Responsible Advertising and Marketing Standards (RAMS).

The advertising and marketing code, which was made public Oct. 8, includes a set of guiding principles to ensure that Cresco markets and promotes its brands and products responsibly. The standards include guidance on commercial communications to help prevent underage appeal and ensure companies make appropriate claims about cannabis’s benefits. The code also offers best practices for consumer-facing promotional events and merchandising.

Here, Cresco COO Greg Butler and SVP of Brand Marketing Cory Rothschild share why the company developed and published these standards, as well as how they will ultimately benefit the industry as it continues to grow.

Melissa Schiller: Why did Cresco develop these standards? What was the company’s overall goal in releasing these to the industry?

Photos courtesy of Cresco Labs

Cresco COO Greg Butler

Greg Butler: The reason why we wanted to publish this is, as we look to the end of this year and into next year, what we expect to see in the U.S. cannabis market is an increase in investment across all companies in building their brands. There are a couple key trends driving that. One is competition that continues to grow, so everyone is fighting to grow their brand with customers. The second is companies are strengthening their financial positions. They’re able to invest more in brands. And then the third is we’re also seeing more opportunities for cannabis brands to invest in marketing, so there are more ways they can spend money. With that, there are a lot of tailwinds that are driving toward more spend for brands in the space.

As we looked at it, as we’re competitive and we expect everyone to be competitive, we wanted to create some guidelines that set a series of best practices to ensure that we’re building brands the right way and that it’s always in service of what’s best for consumers.

Cory Rothschild: We obviously operate under different laws and regulations in every state that we compete in. Foundationally, we do believe that there are some standards that shouldn’t change or vary depending on where you’re talking about cannabis. Even in certain states that have more relaxed laws, there are certain things when it comes to conversations around promoting responsible consumption or avoiding underage-appealing imagery. Those don’t change, and we must commit to those as an industry, not even just as a company, if we’re going to build a category that not only reaches its potential, but does what is best for consumers along the way.

MS: What do Cresco’s Responsible Advertising and Marketing Standards entail? What are some key best practices that are outlined in these standards?

CR: If you look at our guidelines, in some ways, it’s just some things that shouldn’t even be up for debate, from [the fact that] you should never advertise to a minor to how [to] display pictures of people and images in your ads to the claims that you make, and then how do you run events to ensure we’re doing everything in our ability to operate in a way in which a young consumer wouldn’t see our marketing? So, the gambit of our code reaches everything from media through to experience.

MS: What was the overall process like for developing these standards?

CR: It started with developing our own internal standards and adhering to those in all the work that we do on an ongoing basis. Our company is founded on being professional and helping to normalize the industry, and what that [means] is holding ourselves to standards that are above what is being asked of us. So, we developed this set of norms to what we felt was appropriate and to what we believed was the right way to operate our business.

We did look to other codes and responsible use practices that exist in the broader CPG space, whether that’s in alcohol or pharmaceuticals, to look to how we could set our own industry standards above and beyond the regulations that are imposed on us currently to make sure that we are proactively building the right category.

MS: How will these standards help prevent underage consumption?

Cresco SVP of Brand Marketing Cory Rothschild

CR: I would hope that these standards are overwhelmingly a no-brainer for most people. We hope that people nod as they read them because they seem reasonable and responsible. So, to point to a few—one is that when we show individuals in our advertising, those people should be over the age of 21, and that should be made clear in the ways in which they’re shown. This is something that’s commonly practiced across other CPG categories where there are age restrictions around usage, and there’s no reason we shouldn’t be doing the same. There are examples within our industry where there are underage individuals being shown or at least seemingly underage individuals being shown in advertising that wouldn’t be appropriate.

The other piece is showing imagery that would be somehow juvenile, whether that’s a logo, an endorsement, [or] some sort of imagery or dress that connotates use or young culture. That’s not appropriate to connect to cannabis when you’re building and making advertising. That’s something that we believe is common sense, but it’s worth us committing to as a group because we know that this is a product that can have an appeal to underage individuals if frequently shown in advertising.

MS: How will these standards help Cresco and other cannabis advertisers make appropriate claims about cannabis’s benefits?

GB: One of the things that’s difficult in an industry like cannabis is you don’t have a lot of FCC guidelines or health and safety guidelines of what product claims you can or cannot make. There isn’t a lot of oversight for brands that are making claims. As you think of an industry that’s brand new with consumers, you don’t want to allow brands to make misleading statements that might cause confusion or even misuse of products. So, in a world where you’re not governed by bodies that ensure you’re using clinical trials, we want to encourage everyone to be responsible on how they make or allude to product claims associated with product.

MS: How do the standards help establish best practices for promotional events and merchandising?

CR: I think the part that is unclear at the local level is, how should companies interact with people who are under 21 with product? Of course, if you’re hosting an event in California that has a license to sell cannabis, that’s a 21-and-over event by definition and is obviously associated with ID checking and all kinds of age gating, but that’s not the case when you’re putting up a booth at a community fair or a booth at an arts festival. These are all things [where] anyone can have a booth or show up, and you have to make judgement calls around whether or not you’d like to participate in those events. Then, when individuals at the event want to approach your booth and have a conversation with your company, how do you make sure you’re having appropriate conversations with appropriate individuals?

A lot of the code is trying to fill in some of those gray spaces that we’ve run into as a company on a daily basis as we try to do different events in different states. These are meant to be a complement to existing regulation and law as opposed to either rewriting or stating the obvious.

An example of Cresco’s advertising for its Liquid Live Resin

MS: How will these standards be distributed, or how do you hope they will be adopted by the industry?

GB: Our hope by publishing them is that it’s somewhat of a call to action. We hope that everyone looks at their own business and maybe finetunes and creates their own [standards]. While we’re all building our brands, we all want to do it the right way, so we’ll make [our standards] publicly available on our website for anyone who wants to read [them], and our only real objective on this is that others read, understand and adapt to it or their own version.

CR: Just to build on that, we’ve gotten a great response from other businesses that are interested in partnering, and we’re just beginning to have some of those conversations. My hope is that this becomes bigger than just Cresco Labs, as Greg mentioned, and that it pushes us to work together as an industry to build what’s right for our category. We [want to] continue to open more and more opportunities with partners in the media space, vendors [and] agencies so that more people are able to participate in cannabis and we can have greater and better marketing overall.

Editor’s Note: This interview has been edited for style, length and clarity.

Published at Sat, 17 Oct 2020 12:30:00 +0000

New Mexico Judge Wants To Loosen Medical Cannabis Reciprocity

New Mexico Judge Wants To Loosen Medical Cannabis Reciprocity

Reciprocity has long been an issue in the state of New Mexico, and one that has been up for debate for some time. Now, a district court judge wants to make a change to current law, ruling that reciprocal medical cannabis patients should be able to access cannabis even if they have a recommendation to use medical cannabis from another state. 

If this ruling passes, those with New Mexico medical cannabis cards will be able to get cannabis in other states that allow reciprocity, and those with cards from other states will be able to get cards in New Mexico. This will expand the industry and the patients flooding in to use medical cannabis in New Mexico. 

“The court held that a reciprocal patient can have a proof of authorization and an ID from different jurisdictions, because the department was trying to say that, that you could only become a reciprocal patient if you had your proof of authorization, and your ID from the same jurisdiction,” said Jacob Candelaria, attorney for Ultra Health, a New Mexico-based medical cannabis producer who wants to see this change happen and filer to have this new order passed. 

Read More

Published at Fri, 16 Oct 2020 15:12:17 +0000

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) — MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:
 

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”

About the London Stock Exchange
The London Stock Exchange was founded in 1571 during the reign of Elizabeth I in London, England. The LSE is the 4th largest exchange in the world (based on total market value of its listed companies) and is currently ranked 7th in overall liquidity. As of August 2020, the companies listed on the London Stock Exchange have a combined market capitalisation of ~$4 trillion USD (GBP ~£3,084,232,000,000). Its current premises are situated in Paternoster Square close to St Paul’s Cathedral. It is part of publicly traded London Stock Exchange Group (LSEG).

About Boustead & Company Limited
Boustead & Company Limited is a diversified and comprehensive non-bank financial institution with offices in Los Angeles, New York, San Francisco, London, and Beijing that is rapidly expanding in growth markets throughout the US and Asia. Through its principals and fully licensed subsidiaries, Boustead & Company possesses rich experience and exceptional capabilities in capital markets deal execution and provides best-in-class one-stop financial services to clients. Boustead’s comprehensive financial services platform consists of four operating units: Boustead Securities, LLC a US-based FINRA Broker/Dealer and middle-market investment bank; Sutter Securities Group, Inc., which owns four FINRA-regulated entities: Sutter Securities, Inc., Sutter Securities Clearing, LLC and FlashFunders Funding Portal, LLC, along with Sutter Securities Financial Services, Inc., Sutter Capital Partners, LLC a California Registered Investment Advisor; and Boustead Capital Markets LLP, regulated as an appointed representative in the UK. For more information, please visit www.bousteadco.com.
On behalf of Boustead & Company
Limited
Dan McClory, CEO
dan@boustead1828.com

About Boustead Capital Markets, LLP
Boustead Capital Markets, LLP, based in London, advises on a wide array of corporate finance assignments across many industries, and is an appointed representative of Thornbridge Investment Management LLP which is authorised and regulated by the FCA. Boustead Capital Markets is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution.
On behalf of Boustead Capital Markets,
LLP

David Peerless, Director
david@boustead1828.com

About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ (CSE: MYCO) is a publicly traded life sciences syndicate, with offices in Denver, CO, USA and Vancouver, BC, Canada. Mydecine is dedicated to the development and production of adaptive pathway medicine and natural health products all stemming from mushrooms. Mydecine’s experienced multi-talented team has the dynamic capabilities to oversee all areas of Schedule I drug development, including but not limited to synthesis, genetic research, delivery mechanism design, clinical trial execution; through to worldwide product commercialization, marketing and spore-to-sale distribution of cGMP psilocybin API’s and non-psychedelic medicinal fungi. By leveraging strategic partnerships with global scientific, medical, clinical, and Veteran organizations; Mydecine is well positioned at the forefront of naturally derived medicine, alternative therapeutics, and fungtional™ mushroom vitality consumer goods. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus together on providing innovative and effective solutions that can help millions of people live a healthier quality life.

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

On behalf of the Board of
Directors:

Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

Corp Communication:
Charles Lee, Investor Relations
corp@mydecineinc.com

Public Relations:
Cynthia Salarizadeh, Public Relations
pr@mydecineinc.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
 

Published at Fri, 16 Oct 2020 20:16:58 +0000

Massachusetts Cannabis Cultivators Benefit from RII Services

Massachusetts Cannabis Cultivators Benefit from RII Services

Ready or not, cannabis regulators are watching you. 

What was once considered a subversive or fringe industry has blossomed into a vast, complex, multifaceted sector all its own over the past decade. And with those changes have come a much-increased regulatory presence.

Proper labeling is paramount these days, while testing for potency, pesticides, microbials and more is commonplace. But here’s the thing: Those cannabis- and hemp-specific mandates, important as they are, are barely the tip of the regulatory iceberg compared to what’s coming down the pike.

Regulations from the likes of the Occupational Safety and Health Administration (OSHA) and the Food and Drug Administration (FDA) are essential for ensuring safety of workers and consumers and further legitimizing the hemp and cannabis industries as a whole. But unless cultivators, processors and dispensaries make some changes now, they’ll be playing catch-up for years to come—many with suboptimal consequences. 

Kim Stuck, Founder and CEO of Allay Consulting

As the world’s first cannabis and hemp specialist for a major metropolitan public health authority at Denver’s Department of Public Health and Environment, where I worked for nearly four years, I witnessed countless well-meaning operators (and their investors) get tripped-up by rules and regs that aren’t always black and white. My work as a regulator now informs everything I do in advising my cannabis and hemp clients. 

As regulatory agencies at every level are stepping up their presence in these still-new industries, here are a couple of the lessons to help you and your colleagues steer clear of trouble. 

A Maturing Industry 

In my years spent as a regulator, which included hundreds of investigations of cannabis and hemp businesses of every kind, I saw the industry transform from one in which blatant non-conformances were rampant (think: no-label brownies in unsealed baggies on dispensary shelves) to one with increasingly stringent consumer safety standards. The industry has rapidly grown up, especially in states with well-established regulated markets like Colorado. And those changes come, in large part, as a result of exacting attention to detail and putting in a lot of hard work. 

Since I’ve crossed the regulatory fence to work as a business consultant, I’ve worked with many cannabis owners, operators and investors who are passionate about their businesses and who openly embrace regulatory compliance because it instills consumer trust. But let’s face it: Not everyone is an expert on food safety protocols or OSHA codes. 

To borrow a common phrase, you don’t know what you don’t know. And in this rapidly maturing and increasingly regulated industry, that can lead to big problems. 

Whether you’re launching a new facility, have recently acquired an existing business or perhaps received a less-than-stellar health inspection, it’s smart to regularly assess your operation from the top down. Inspectors pay close attention to certain things: working hand sinks, personal protective equipment (PPE), documentation, contamination avoidance and worker safety, to name a few.

And because outside perspectives are essential in any highly regulated industry, my first recommendation to operators and investors is always to seek advice from a regulatory expert—and then honestly identify key areas in need of improvement at their facilities. 

Once you have taken an honest look at your operation and have a grasp on what needs work, you can make a plan of action and implement necessary changes. Companies that embrace this type of self-assessment and self-improvement almost always sail through regulatory checks with health departments, fire inspectors and the like. Removing the stress of noncompliance allows them to focus on what really matters: growing their business. 

As regulated cannabis markets take root across the country and cannabinoids find their way into more and more consumable products—baked goods, tinctures, supplements, confections, body products and more—much of the industry will inevitably find itself subject to the same regulations as mass-market food and cosmetics manufacturers. But unlike those industries, there’s no real precedent for intense regulation in the cannabis industry. Many cannabis operators aren’t familiar with the rigorous mandates that accompany federal regulatory oversight—and the consequences of noncompliance with federal bodies, like FDA or OSHA, are far steeper than any state cannabis-specific penalties.

Think Long-Term Starting Now

There’s a lot on the cannabis policy reform horizon right now. Several states, including New Jersey and Arizona, are voting on legalization for adult use in the upcoming election. And many insiders predict that successful legalization in those states will usher in a period of rapid political change and widespread legalization—likely leading to federal legalization. This would ease numerous burdens currently placed on the industry by the current patchwork of state laws, but it will also open up companies to much stricter federal health and safety regulations. 

So, that’s the mindset everyone in the industry should have when they evaluate their compliance levels. 

You absolutely do not want to be operating a noncompliant facility when OSHA or the FDA comes knocking. I cannot underscore that enough. And I can say with certainty that it’s the proactive organizations that will find success in the federally legal landscape, while those that drag their feet implementing strict, compliance-minded standard operating procedures (SOPs) will most certainly drop like flies. 

To that end, it’s a great idea to earn any certifications your organization has been considering and to upgrade your facilities and processes now. It can make a huge difference and help your organization get ahead of the regulatory curve—and the competition. 

For example, I recently worked with a processing facility as it earned a Current Good Manufacturing Practices (cGMP) certification. This certification ensures that facilities and processes to create foods or drugs are safe and takes into account safety at every stage of the process—from handling to packaging. Together, we established strong quality management systems, hygiene protocols and safe handling practices. The FDA considers cGMP the baseline in consumer safety practices—and it’s an essential certification for any cannabis and hemp manufacturing, cultivation or processing organization looking to grow in a nationally legalized landscape. 

Another client of mine worked with raw cannabis oil. Everything seemed to be in alignment: They had proper SOPs in place, good hygiene practices and adequate fire safety measures across the facility. But the temperature at which they were storing their oil was problematic and could have led to the proliferation of microbes that could lead to toxins in their end product—a serious operational issue. They were intent on doing things by the book, but until a trained regulatory expert evaluated their facility, they hadn’t considered the headaches that something like improper refrigeration temperatures might cause when it came to their local health department.

Good Intentions Can Have Bad Consequences

Even facilities that scrupulously document their processes with the very best of intentions for their workers may be in violation of regulations without even realizing it.

Here’s an example: Say the general manager of a processing facility offers workers masks to protect them against dust in the manufacturing process. Great, right? Sure—but not from a regulatory standpoint.

In order to be compliant with OSHA, before even putting masks on (including N95s and respirators), workers first need to fill out forms stating they’re healthy enough to even wear them. When OSHA comes around for an inspection and discovers that workers never completed these forms, the fine can be up to $25,000 per worker—for what would have taken someone with experience in the regulatory space about five minutes to flag. 

Success in this industry, from a regulatory standpoint, is truly dependent on details. When a regulatory agent isn’t knocking on your door, it’s easy to put tasks, like creating SOPs or making sure you have proper fixtures, on the backburner. But there’s no reason to risk your business on a bad evaluation—and from what I’ve seen, about 90% of facilities have at least one practice, SOP or safety protocol that could put them in jeopardy. 

Don’t wait for the FDA to tell you that cleaning with isopropyl is not a sanitization step or for OSHA to penalize you for not having a Hazard Communication Plan. Do the work now, and reap the benefits for years to come. Because the regulators are circling—whether you’re ready for them or not.

Kim Stuck is the founder and CEO of Allay Consulting, a compliance strategy and services provider serving the hemp and cannabis industries nationwide. During her tenure as a cannabis and hemp specialist with the City of Denver, Stuck worked as an investigator covering cultivation, manufacturing and retail.     

Published at Thu, 15 Oct 2020 17:38:00 +0000

Bruce Linton-Backed Gage Cannabis Launches Reg A+ Equity Financing

Bruce Linton-Backed Gage Cannabis Launches Reg A+ Equity Financing

Gage Cannabis Co., the leading high-quality craft cannabis brand and operator in Michigan, today launched a Regulation A, Tier 2, equity financing (see Gage Cannabis Co. Offering Circular).

As the exclusive cultivator and retailer of world-leading cannabis brands including Cookies, Lemonnade, Runtz, Grandiflora, SLANG Worldwide (CNSX:SLNG), OG Raskal, and its own proprietary Gage brand portfolio in Michigan, Gage is strategically positioned to become the retailer of choice among adult-use and medical cannabis consumers. The Company has opened five provisioning centers (dispensaries) and is in the process of opening three more locations by the end of the year and over 20 stores by the end of 2021. The Company has achieved US$30+ million (unaudited) in sales so far this year and is anticipating further sales growth in the coming months.

“We wanted to provide investors with the opportunity to invest in a growing and dominant cannabis operation before an official IPO process,” said Bruce Linton, Executive Chairman of Gage Cannabis. “Michigan is one of the top cannabis markets in the U.S., and I am confident Gage is poised to continue building on its historical execution and fortifying its position as one of the top operators and brands in Michigan, as well as a name consumers look for across the United States”.

Linton is the former CEO, Chairman and Founder of Canopy Growth Corporation (TSX:WEED) (NYSE:CGC), which he transformed from a concept into one of the most recognizable and valuable cannabis companies in the world. Linton is a passionate entrepreneur and brings a wealth of experience and unparalleled expertise in a variety of industries, creating unprecedented long-term shareholder value. Linton was the first and lead investor in this Offering, further emphasizing his support of the Company.

“We’re excited to invite public investors to join alongside industry juggernauts, like Bruce Linton, and provide them with the opportunity to participate in our future success,” said Fabian Monaco, President of Gage Cannabis. “We have strategically acquired a portfolio of high-quality operating assets and brands in the rapidly growing Michigan market and developed a reputation for providing consumers with access to craft cannabis in elevated retail environments. This is a great first step in our journey to becoming a publicly-traded company and we’re excited to continue to build on our strong foundation while delivering long-term shareholder value.”

Gage is offering up to 28,571,400 shares of Subordinate Voting Shares (“Shares”), for US$1.75 per Share. The Shares are being offered pursuant to Regulation A of Section 3(b) of the Securities, as amended, for Tier 2 offerings, by management on a “best-efforts” basis directly to purchasers who satisfy the requirements set forth in Regulation A. 

The Company encourages all interested investors to visit GageInvestors.com for a link to the Offering Circular and to learn how to invest in the Offering. Financing information is also available by calling toll free at 1-844-606-0809 or locally at 1-616-504-6060.

About Gage Cannabis Co.

Gage Cannabis Co. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market. Through years of progressive industry experience, the firm’s founding partners have successfully built and grown operations with federal and state licenses, including cultivation, processing and retail locations. Gage’s portfolio includes city and state approvals for 19 “Class C” cultivation licenses, three processing licenses and 13 provisioning centers (dispensaries). To learn more, please visit GageInvestors.com.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable U.S. federal money laundering legislation.  Investors should carefully read the risk factors and disclosures contained in our offering circular before making any decision to invest in our company.  

Forward Looking Information

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Legal Notice

This press release is for information purposes only and does not constitute an offer or sale of the securities referenced herein.  Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A, Tier 2 of the Securities Act of 1933. A link to the qualified offering circular and related offering documents is attached hereto and all prospective investors should carefully review these materials, which includes important disclosures and risk factors associated with an investment in Gage Cannabis Co. These securities have not been recommended by the Securities and Exchange Commission or any state securities commission or regulatory authority, nor has any commission or regulatory confirmed the accuracy of the information contained the offering materials.  

The information is provided for convenience only, is not investment advice and may not be relied upon in considering an investment in Gage Cannabis Co.  No representation or warranty, express or implied, is made as to the accuracy or completeness of any information contained herein, and any investment decision should be based solely on the information contained in the offering circular and related materials, and the investors independent research. No representation or warranty, express or implied, is made as to the future performance of any investment in Gage Cannabis Co., or that investors will or are likely to achieve favorable results, will make any profit at all or will be able to avoid incurring a loss on their investment.  In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine whether an investment in Gage Cannabis Co. is suitable for them.

Should you have any questions or would like follow-up information, please do not hesitate to contact ir@gageusa.com.

Share

Share - Facebook


Share - Twitter

Published at Wed, 14 Oct 2020 12:08:04 +0000

Will A Biden/Harris Presidency Be A Friend Or Foe Of The Cannabis Industry?

Will A Biden/Harris Presidency Be A Friend Or Foe Of The Cannabis Industry?

Last week, the cannabis sector rallied after Kamala Harris’ debate with Vice President Mike Pence. We believe the reason for the move higher is related to Harris stating that cannabis would be decriminalized under a Joe Biden administration.

In late 2019, Pew Research Center conducted a survey that found that two-thirds of Americans believe that cannabis should be legal. The survey also found that there has been a significant decline in the number of adults who believe that cannabis should be illegal. According to the survey, the percentage of adults who oppose the legalization of cannabis has fallen from 52% in 2010 to 32%.

Numbers do not lie, and the American people want cannabis to be legalized. The COVID pandemic put considerable pressure on the global economy and the US economy was not immune to this. States desperately need money and are looking for additional revenue streams in a post-pandemic world.

As it relates to economies (state and federal) finding new revenue streams, the legalization of sports betting was the first domino to fall. The change in regulation has been a catalyst for the US economy (and stock market) and several sports betting companies have recently gone public and are valued at more than $50 billion in aggregate (Draft Kings and Penn National Gaming).

We believe that the legalization of cannabis would prove to be an even larger taxable revenue stream than sports betting. States need more revenue and we expect cannabis to draw new voters to the polls and play an important role in the outcome of the November election.

If you are a US cannabis company, the current regulatory environment is a nightmare and has made operating a challenge for even the largest of US cannabis companies. Since cannabis is still illegal at the federal level, banks and other traditional financial institutions have largely refused to work with cannabis companies.

If cannabis is decriminalized, companies will be less at risk of being robbed as there will be substantially less cash on hand.  If companies have access to safe banking, it would be a massive catalyst for the cannabis industry as it would allow companies to access the US capital market and it would lower the risk of operating a cannabis business

As of October 9th, the top 12 US multi-state operators (MSO) were valued at more than $15 billion. That is impressive for an industry that faces hurdles where companies are pretty much forced to spend millions on unnecessary US regulatory expenses such as:

  • It is tough for companies to get insurance and most are unable to (if you get robbed, you cannot recover losses)
  • Companies spend an exceptional amount of money to meet the regulations that are associated with product packaging which require an excessive amount of plastic to be used
  • The legal costs and the amount of time that are associated with completing acquisitions are well above average
  • Companies face additional taxes on the state and federal level
  • If a company wants to enter a new market (or enter the industry), the costs associated with the process are well above average
  • On the real estate side of the business, companies have to pay extremely high prices

If cannabis is decriminalized, we expect the market to record incremental growth on a going forward basis. We believe that US cannabis companies are in the early innings of a multi-decade growth cycle. Once cannabis is decriminalized, US companies would quickly start taking market share from Canada and believe that we are in the middle of a major transformation.

We believe that the decriminalization of cannabis will level the playing field for cannabis companies on the global level. If Biden wins and Harris follows through on this, decriminalization will allow companies to expense normal operational costs instead of being taxed on gross profit.

The US cannabis industry is at an infection point and a Biden victory could be the catalyst we need for the sector to be able to scale. We believe that it would be easy for US cannabis companies to take over international markets where Canada is leading the charge.

If you are familiar with the cannabis industry, then you are familiar with the big players in the space. If the cannabis is decriminalized, we expect to see some consolidation and many companies would benefit from this. Some of the companies that we believe to be flying under the radar and would benefit from this but are not limited to: Jushi Holdings, C21 Investments, Stem Holdings, Cresco Labs, Acreage Holdings and Innovative Industrial Properties.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 13 Oct 2020 11:37:45 +0000